The partnership between Evotec and the Crohn's & Colitis Foundation is a strategic move to enhance Evotec's drug discovery and development capabilities, which could be beneficial in the long run. However, the immediate market reaction has been negative, as reflected by the 2.53% drop in EVO's stock price. This could be due to a variety of factors, including market conditions, investor expectations, or the lack of financial details about the partnership. The short-term impact is negative, but the long-term outlook could improve as the collaboration progresses and yields potential therapeutic candidates.